HUTCHMED (China) Limited
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Chig Fung Cheng
- Full Time Employees
- 1,796
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Cheung Kong Center Hong Kong Hong Kong
- IPO Date
- Jun 30, 2021
- Website
- hutch-med.com
- Similar Companies
- Business
- HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.
Company News
HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
Braveheart Bio: In Non-Obstructive HCM, The Therapeutic Window Is The Product
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Stock Has Consensus Price Target of $14.87 According to Analysts
ADP Warns of Cooling Labor Market While Its Own Business Feels the Chill
Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More
AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
New 3Sixty Insights Analysis Reinforces the Importance of Insperity's HRScale Service-Enabled HR Solution
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data
Workday Named a Leader in Inaugural 2026 Gartner® Magic Quadrant™ for Workforce Management Technology
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy
HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 Transcript
Panmure and Cavendish reiterate buy on Hutchmed after GSK deal
HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal
HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
Workday Named a Leader in 2026 Gartner® Magic Quadrant™ for Cloud HCM Suites for 1,000+ Employee Enterprises for Eleventh Consecutive Year
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China